Price
No data yet.
Social Signal Score
Analyst Ratings
33 analystsRevenue
$628.69M+910.85%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael Morrissey
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,077
- Beta
- 0.42
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 16.14
Financials
Revenue
$628.69M+910.9%Net Income
$212.05MEBITDA
$262.68MFree Cash Flow
$298.43MEPS (diluted)
$0.82Shares Outstanding (diluted)
259.68M+1.3%Operating Expenses
$359.62MCash & Debt
$839.38MReturn of Capital
$322.97MRevenue by Segment (annual)
$4.64BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.32B | $782.57M | $2.88 |
| 2024 | $2.17B | $521.27M | $1.80 |
| 2023 | $1.83B | $207.76M | $0.65 |
| 2022 | $1.61B | $182.28M | $0.57 |
| 2021 | $1.43B | $231.06M | $0.73 |
| 2020 | $987.54M | $111.78M | $0.36 |
| 2019 | $967.77M | $321.01M | $1.06 |
| 2018 | $853.83M | $690.07M | $2.32 |
| 2017 | $452.48M | $154.23M | $0.52 |
| 2016 | $191.45M | $-70.22M | $-0.28 |
| 2015 | $37.17M | $-169.74M | $-0.81 |
| 2014 | $25.11M | $-268.54M | $-1.38 |
| 2013 | $31.34M | $-244.76M | $-1.33 |
| 2012 | $47.45M | $-147.65M | $-0.92 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $4.23
- Implied price
- $63.51
- Return from $58.39
- 1.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $31.58 — -45.9% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 11 | 13 | 15 | 17 | 19 |
|---|---|---|---|---|---|
| -2.0% | -13.3% | -10.3% | -7.7% | -5.4% | -3.3% |
| 3.0% | -8.8% | -5.7% | -3.0% | -0.6% | 1.7% |
| 8.0% | -4.4% | -1.2% | 1.7% | 4.3% | 6.6% |
| 13.0% | 0.0% | 3.4% | 6.4% | 9.1% | 11.6% |
| 18.0% | 4.4% | 8.0% | 11.1% | 13.9% | 16.5% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70Social Signal Score
Mentions (25)
- Newszacks.com·5d ago·Positive
Exelixis (EXEL) is a Top-Ranked Growth Stock: Should You Buy? Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newszacks.com·11d ago·Neutral
Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans? Exelixis faces a three-month FDA review delay for zanzalintinib, pushing the potential CRC decision to March 2027.
View source ↗ - Newszacks.com·12d ago·Positive
Here's Why Exelixis (EXEL) is a Strong Momentum Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗ - Newsmarketbeat.com·18d ago·Neutral
Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3B Exelixis NASDAQ: EXEL President and CEO Michael Morrissey said the company is focused on expanding its oncology franchises through internal development, selective business development and potential collaborations, while preparing for a planned launch of zanzalintinib in metastatic colorectal cancer.
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Exelixis, Inc. (EXEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Exelixis, Inc. (EXEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsmarketbeat.com·21d ago·Neutral
Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle Exelixis NASDAQ: EXEL executives outlined plans to continue expanding the CABOMETYX franchise while preparing for a potential launch of zanzalintinib, or zanza, in colorectal cancer later this year.
View source ↗ - Newszacks.com·21d ago·Positive
Here's Why Exelixis (EXEL) is a Strong Growth Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - News (RSS)seekingalpha·22d ago·Neutral
Exelixis: The FDA Delay Costs Less Than The Market Thinks
View source ↗ - Newsmarketbeat.com·22d ago·Negative
Exelixis Eyes CABOMETYX Growth, Zanzalintinib Catalysts Across Cancer Franchises Exelixis NASDAQ: EXEL executives outlined a franchise-focused growth strategy centered on expanding CABOMETYX across renal cell carcinoma and neuroendocrine tumors while advancing zanzalintinib through multiple late-stage studies.
View source ↗ - Newsseekingalpha.com·22d ago·Negative
Exelixis: The FDA Delay Costs Less Than The Market Thinks The FDA extended its review of Exelixis' zanzalintinib by three months, but no new clinical failure or safety signal was disclosed. At a 10% discount rate, three months reduces an asset's present value by only 2.35%, far less than Exelixis initially lost. CABOMETYX continues growing, and 2026 guidance includes no zanzalintinib launch revenue.
View source ↗ - News (RSS)yahoo·24d ago·Negative
Exelixis, An IBD 50 Stock, Pulls A Bearish Move With Surprise Cancer Delay
View source ↗ - Newsbenzinga.com·24d ago·Negative
Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In On Friday, the U.S. Food and Drug Administration (FDA) extended the review period for Exelixis Inc.‘s (NASDAQ:EXEL) new drug application (NDA) for zanzalintinib, in combination with atezolizumab, for metastatic colorectal cancer by three months.
View source ↗ - News (RSS)investing·24d ago·Neutral
Exelixis stock falls as FDA extends zanzalintinib review
View source ↗ - Newsreuters.com·25d ago·Negative
U.S. FDA extends review of Exelixis' cancer drug The U.S. Food and Drug Administration has extended the review of Exelixis' experimental colorectal cancer drug combination by three months, the company said in a filing on Friday.
View source ↗ - Newsseekingalpha.com·26d ago·Positive
Exelixis, Inc. (EXEL) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Exelixis, Inc. (EXEL) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
View source ↗ - News (RSS)seekingalpha·27d ago·Positive
Exelixis, Inc. (EXEL) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·27d ago·Positive
Exelixis, Inc. (EXEL) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Exelixis, Inc. (EXEL) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newszacks.com·31d ago·Neutral
Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue? Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?
View source ↗ - News (RSS)seekingalpha·34d ago·Negative
Exelixis: 'Hold' On Zanzalintinib Subpopulation Miss And STELLAR-304 H2 2026 Data
View source ↗ - Newsseekingalpha.com·35d ago·Negative
Exelixis: "Hold" On Zanzalintinib Subpopulation Miss And STELLAR-304 2H 2026 Data Exelixis is downgraded from "Strong Buy" to "Hold" due to lowered 2026 revenue guidance and mixed clinical trial outcomes. Zanzalintinib + TECENTRIQ achieved overall survival benefit in mCRC, but missed the non-liver metastases subgroup endpoint; FDA PDUFA date set for December 3, 2026. Q2 2026 revenues rose to $628.7M, but future sales growth is uncertain and full-year guidance was cut to $2.500–$2.550B.
View source ↗ - News (Marketaux)gurufocus.com·35d ago·Positive
EXEL Looks 18.3% Overvalued on GF Value™ After Patent Win On August 31, 2026, Exelixis <e[+313 characters]
View source ↗ - Newsbusinesswire.com·35d ago·Neutral
Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil Action No. 22-00228 (Consolidated), the U.S. Court of Appeals for the Federal Circuit (Appeal No. 25-1236) has affirmed a key portion of the 2024 judgment of the U.S. District Court for the District of Delaware in Exelixis' favor. The …
View source ↗ - Newsfxempire.com·38d ago·Positive
Strong Sales, Earnings Send Exelixis Shares Higher Exelixis, Inc. (EXEL) shares enjoying institutional support – up 43.5% in a year.
View source ↗ - Newszacks.com·46d ago·Positive
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗ - Newsbusinesswire.com·50d ago·Negative
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $EXEL--EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law.
View source ↗
Earnings
Tue, Nov 3(in 4 weeks)
Consensus estimate $0.88 per share
Typical surprise +13.9% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$0.91 vs $0.85beat
- Tue, May 5$0.87 vs $0.77beat
- Tue, Feb 10$0.94 vs $0.77beat
- Tue, Nov 4$0.78 vs $0.69beat
- Mon, Jul 28$0.75 vs $0.65beat
- Tue, May 13$0.62 vs $0.36beat
Estimates and results for EXEL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by EXEL officers and directors.
- Bought
- $1.2m
- Sold
- $41.2m
1 trade
30 trades
- Beckerle Mary Csold
- Wyszomierski Jack Lsold
- Eckhardt Sue Gailsold
- Aftab Danasold
- Haley Patrick J.sold
- Senner Christopher J.sold
- Hefti Brendasold
- Beckerle Mary Csold
69 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Ro Khannahouse · CA17 · disclosed Feb 5, 2024 (26d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jan 3, 2023 (28d later)Buy$1,001 - $15,000
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (328d later)Sell$1,001 - $15,000
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (377d later)Sell$1,001 - $15,000
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (446d later)Buy$1,001 - $15,000
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (474d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.